XML 30 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements Income and Comprehensive Income - USD ($)
shares in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues:      
Revenues $ 1,133.5 $ 1,045.9 $ 788.1
Operating expenses:      
Cost of sales 14.3 10.1 7.4
Research and development 328.1 275.0 200.0
Acquired in-process research and development 105.3 164.5 154.3
Selling, general and administrative 583.3 433.3 354.1
Total operating expenses 1,031.0 882.9 715.8
Operating income 102.5 163.0 72.3
Other (expense) income:      
Interest expense (25.8) (32.8) (32.0)
Unrealized gain (loss) on equity securities 20.9 (17.7) (13.0)
Loss on extinguishment of convertible senior notes 0.0 (18.4) 0.0
Investment income and other, net 3.8 12.6 19.2
Total other expense, net (1.1) (56.3) (25.8)
Income before provision for (benefit from) income taxes 101.4 106.7 46.5
Provision for (benefit from) income taxes 11.8 (300.6) 9.5
Net income 89.6 407.3 37.0
Unrealized (loss) gain on debt securities available-for-sale (3.5) 0.4 3.4
Comprehensive income $ 86.1 $ 407.7 $ 40.4
Earnings per share, basic (in USD per share) $ 0.95 $ 4.38 $ 0.40
Earnings per share, diluted (in USD per share) $ 0.92 $ 4.16 $ 0.39
Weighted average common shares outstanding, basic (in shares) 94.6 93.1 91.6
Weighted average common shares outstanding, diluted (in shares) 97.9 97.8 95.7
Product sales, net      
Revenues:      
Revenues $ 1,090.1 $ 994.1 $ 752.9
Collaboration revenue      
Revenues:      
Revenues $ 43.4 $ 51.8 $ 35.2